KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Gross Margin (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Gross Margin for 16 consecutive years, with 82.56% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin fell 332.0% to 82.56% in Q4 2025 year-over-year; TTM through Dec 2025 was 83.62%, a 68.0% decrease, with the full-year FY2025 number at 83.62%, down 68.0% from a year prior.
  • Gross Margin was 82.56% for Q4 2025 at Halozyme Therapeutics, down from 84.41% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 86.42% in Q1 2022 to a low of 74.62% in Q3 2023.
  • A 5-year average of 81.15% and a median of 82.14% in 2025 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: crashed -811bps in 2023, then soared 862bps in 2024.
  • Halozyme Therapeutics' Gross Margin stood at 78.84% in 2021, then dropped by -3bps to 76.79% in 2022, then rose by 1bps to 77.27% in 2023, then increased by 11bps to 85.89% in 2024, then fell by -4bps to 82.56% in 2025.
  • Per Business Quant, the three most recent readings for HALO's Gross Margin are 82.56% (Q4 2025), 84.41% (Q3 2025), and 85.77% (Q2 2025).